OBJECTIVE: High consumption of ω-3 polyunsaturated fatty acids (PUFAs) has been associated with lower plasma homocystine (Hcy) levels, but intervention studies in humans have been inconclusive. The objective was to systematically evaluate the effects of ω-3 PUFA supplementation on plasma Hcy levels. METHODS: A comprehensive search of Medline, EMBASE, the Cochrane Clinical Trials Registry, and bibliographies of relevant articles published from 1966 through September 2010 was undertaken. All randomized, placebo-controlled trials that compared ω-3 PUFA supplementation with placebo were included. Two investigators performed data extraction and quality scoring independently, with discrepancies resolved by consensus. RESULTS: Eleven trials including 702 subjects were analyzed. The outcomes studied were plasma Hcy level. Eleven randomized, placebo-controlled trials were included in this meta-analysis. Supplementation with ω-3 PUFAs was associated with a significant decrease in plasma Hcy level (weighted mean difference -1.59 μmol/L, 95% confidence interval -2.34 to -0.83) compared with control subjects. CONCLUSION: This meta-analysis suggested that ω-3 PUFA supplementation can decrease plasma Hcy levels. The implications of these findings remain to be elucidated.
OBJECTIVE: High consumption of ω-3 polyunsaturated fatty acids (PUFAs) has been associated with lower plasma homocystine (Hcy) levels, but intervention studies in humans have been inconclusive. The objective was to systematically evaluate the effects of ω-3 PUFA supplementation on plasma Hcy levels. METHODS: A comprehensive search of Medline, EMBASE, the Cochrane Clinical Trials Registry, and bibliographies of relevant articles published from 1966 through September 2010 was undertaken. All randomized, placebo-controlled trials that compared ω-3 PUFA supplementation with placebo were included. Two investigators performed data extraction and quality scoring independently, with discrepancies resolved by consensus. RESULTS: Eleven trials including 702 subjects were analyzed. The outcomes studied were plasma Hcy level. Eleven randomized, placebo-controlled trials were included in this meta-analysis. Supplementation with ω-3 PUFAs was associated with a significant decrease in plasma Hcy level (weighted mean difference -1.59 μmol/L, 95% confidence interval -2.34 to -0.83) compared with control subjects. CONCLUSION: This meta-analysis suggested that ω-3 PUFA supplementation can decrease plasma Hcy levels. The implications of these findings remain to be elucidated.
Authors: C Hooper; P De Souto Barreto; N Coley; E Caussé; P Payoux; A S Salabert; M Cesari; S Andrieu; G-L Bowman; M Weiner; B Vellas Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Bodil Bjørndal; Marie S Ramsvik; Carine Lindquist; Jan E Nordrehaug; Inge Bruheim; Asbjørn Svardal; Ottar Nygård; Rolf K Berge Journal: Mar Drugs Date: 2015-09-08 Impact factor: 5.118
Authors: Biljana A Vuckovic; Velibor S Cabarkapa; Tatjana A Ilic; Iva R Salatic; Zagorka S Lozanov-Crvenkovic; Gorana P Mitic Journal: Croat Med J Date: 2013-10-28 Impact factor: 1.351